A preclinical study led by scientists at the UCLA Jonsson Comprehensive Cancer suggests that heating solid tumours during CAR T-cell therapy can enhance the treatment's success.
The researchers found that when a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumour growth for up to 20 days in mice.
Among the mice that were treated with the combination, 33 percent were still tumour free after the 20-day mark.
The research is published in the journal Advanced Materials.
T cells that have been genetically engineered with chimeric antigen receptor, or CAR, have successfully been used to treat many patients with lymphoma and leukaemia.
But CAR T cell therapy has been less successful for treating solid tumours because the tumours have a protective microenvironment, which makes it harder for the CAR T cells to break into the tumour and keep the T cells activated.
The UCLA scientists decided to test whether combining CAR T therapy with photothermal therapy could overcome that obstacle.
Photothermal therapy is a minimally invasive technique that uses heat from laser energy to kill cancer cells; it is already being used to treat a variety of cancers and other medical conditions.
The researchers tested a mild hyperthermia about 40 degrees Celsius (about 104 degrees Fahrenheit) to see if it could help enhance the CAR T cells to better attack the tumour.
The UCLA-led team tested the technique in mice that were injected with human melanoma tumours.
A photothermal agent was injected into the tumours and then irradiated with the laser to heat them.
Then, CAR T cells were injected intravenously.
Raising the temperature of the laser to about 40 degrees Celsius helped expand blood vessels associated with the tumour, enhancing T cell growth.
By enhancing the power of CAR T cell therapy, the technique could eventually improve the prognosis for people with hard-to-treat solid tumours.
The researchers will continue testing the strategy in animals to optimise the heating duration and temperature before determining whether it can be tested on humans.
Source: University of California - Los Angeles Health Sciences
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.